Novo Nordisk AS has revealed that it has made two offers to acquire Ablynx NV, the Belgian antibody fragment specialist with a drug on the verge of approval for the rare blood condition thrombotic thrombocytopenic purpura (aTTP). The first was made on Dec. 6, 2017, and the second, 14% higher at €2.6bn in cash, on Dec. 22. It said the Belgian firm had "declined to engage in any discussions, despite the proposals which have been put forward."
Novo Nordisk said "combining Ablynx's caplacizumab with Novo Nordisk's strong global hematology franchise and extensive worldwide resources is a compelling...







